Previous Page  6 / 6
Information
Show Menu
Previous Page 6 / 6
Page Background

Volume 9

Journal of Neurology & Neurophysiology

ISSN: 2155-9562

Cognitive Neuroscience 2018

October 18-19, 2018

Page 53

Notes:

conference

series

.com

October 18-19, 2018 | Warsaw, Poland

27

th

International conference on

Neurology and Cognitive Neuroscience

Stephen D Skaper, J Neurol Neurophysiol 2018, Volume 9

DOI: 10.4172/2155-9562-C8-081

Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders

C

ells of the immune system and the central nervous system are capable of interacting with each other. The former cell populations

respond to infection, tissue injury and trauma by releasing substances capable of provoking an inflammatory reaction.

Inflammation is now recognized as a key feature in nervous system pathologies such as chronic pain, neurodegenerative diseases,

stroke, spinal cord injury, and neuropsychiatric disorders such as anxiety/depression and schizophrenia. Neuroinflammation may

also raise the brain’s sensitivity to stress, thereby effecting stress-related neuropsychiatric disorders like anxiety or depression. The

cytokine network plays a large part in how immune systemcells influence the central nervous system. Further, inflammation resulting

from activation of innate immune system cells in the periphery can impact on central nervous system behaviors, such as depression

and cognitive performance. Here, we will present the current state of knowledge which implicates both microglia and mast cells,

two of the principle innate immune cell populations, in neuroinflammation. Further, we shall make the case that dysregulation of

microglia and mast cells may impact cognitive performance and, even more importantly, how their cell-cell interactions can work

to not only promote but also amplify neuroinflammation. Finally, we will use this information to provide a starting point to propose

therapeutic approaches based upon naturally-occurring lipid signaling molecules.

Biography

Stephen D Skaper has completed his PhD in Biochemistry at University of South Dakota and; Laurea in Chemistry at the University of Padua, Italy. He is Adjunct Professor

in Department of Pharmaceutical and Pharmacological Sciences at University of Padua. Prior to this, he was a Senior Group Leader for Neurodegeneration Research,

GlaxoSmithKline Research and Development Limited, UK, and also held academic research positions at the University of California, San Diego. He has authored/co-

authored over 300 research papers, book chapters and monographs, and he is the Editor-in-Chief of CNS and Neurological Disorders Drug Targets. His research interests

focus on the role of immune cells and their interactions in neuroinflammation.

stephen.skaper@unipd.it

Stephen D Skaper

University of Padua, Italy